PTC Therapeutics Inc APHENITY Topline Results Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the APHENITY Top Line Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I will now hand the conference over to your speaker host, Dr. Matthew Klein. Please go ahead.
Thank you all for joining this morning's call. We are excited to share the positive Top Line results of APHENITY, the Phase III trial of Sepiapterin in patients with phenylketonuria.
Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K. We are thrilled to announce that we met the primary endpoint of blood phenylalanine reduction in the APHENITY study with highly statistically significant and clinically meaningful results.
Sepiapterin demonstrated substantial Phe reduction of 63% in the overall primary analysis population and 69% in the subset of classical PKU patients. The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
